Anosmia and Ageusia: Common Findings in COVID‐19 Patients

By L. Vaira, G. Salzano, G. Deiana, G. De Riu. The Laryngoscope, 2020

656 citations recorded by the source corpus.

In a not negligible number of patients affected by COVID‐19 (coronavirus disease 2019), especially if paucisymptomatic, anosmia and ageusia can represent the first or only symptomatology present. Laryngoscope, 130:1787–1787, 2020

Subfields: Complementary and alternative medicine, Neurology, Sensory Systems

View Paper: https://www.semanticscholar.org/paper/497740ef07755d82385a2c5b852ee4fb26a5c37c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Chan
2. Hin Chu
3. K. To
4. Shuofeng Yuan
5. C. Yip
6. O. Tsang
7. Yixin Wang
8. T. Yuen

Citations in the corpus

• Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study (2020, result): “This finding might correlate with the observation that up to 9% of patients with COVID-19 develop confusion or dizzi ness, and some are reported to have anosmia and ageusia, 6, 8, 24 whereas these neurological manifestations were rarely reported in SARS patients.”
• COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection (2021, result): “This finding is consistent with data that points out the SARS-CoV-2 effects on gustatory and olfactory dysfunctions in COVID-19 patients [43, 44].”